SCHEMBL20394170

SCHEMBL20394170

COc1ncccc1-c1cccnc1Oc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.57
MEN1 O00255 2/20 0.57
NPC1 O15118 2/20 0.57
KMT2A Q03164 2/20 0.57
ATM Q13315 1/20 0.57
PDE10A Q9Y233 2/20 0.49
CYP3A4 P08684 1/20 0.46
NAAA Q02083 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
PTGS1 P23219 1/20 0.45
SLC6A2 P23975 1/20 0.45
CYP2C19 P33261 1/20 0.45
PTGS2 P35354 1/20 0.45
SLC6A3 Q01959 1/20 0.45
HIF1A Q16665 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
TNKS2 Q9H2K2 1/20 0.44
MAOB P27338 3/20 0.44
MAPT P10636 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20406788 0.91 NPC1 (0.54) RAB9AMEN1NPC1KMT2AATM
SCHEMBL20394438 0.90 RAB9A (0.53) RAB9AMEN1NPC1KMT2AATM
SCHEMBL20394239 0.86 MEN1 (0.44) RAB9AMEN1NPC1KMT2AATM
SCHEMBL20406203 0.84 PDE10A (0.55) RAB9AMEN1NPC1KMT2AATM
SCHEMBL20394162 0.81 PDE10A (0.49) RAB9AMEN1NPC1KMT2APDE10A
SCHEMBL20406649 0.81 PDE10A (0.41) RAB9AMEN1NPC1KMT2AATM
SCHEMBL20406776 0.79 KMT2A (0.56) RAB9AMEN1NPC1KMT2APDE10A
SCHEMBL20406587 0.79 MEN1 (0.47) RAB9AMEN1NPC1KMT2AATM
SCHEMBL20394347 0.78 KDM4E (0.46) RAB9AMEN1NPC1KMT2AATM
SCHEMBL20406361 0.78 PDE10A (0.47) RAB9AMEN1NPC1KMT2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 EP disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA RAB9A 2057/4885MEN1 2111/4885NPC1 538/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA RAB9A 2057/4885MEN1 2111/4885NPC1 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.